Hard to forecast timing on anything in the pharma world. I think and many here would probably agree, you either invest for the long haul or you dont bother. If you cant stand money tied up or want to constantly flip stocks, then that strategy will dissappoint here, IMO. Just like late last year when the stock out of the blue ran 200-300% that can happen any day here and you blink a few days later and next thing you know it is 1000-2000% higher. Although there is dilution, shares are tight as I believe those shares available in numbers are being soaked up by investors....
If you piece together the inferences and wordings of recent updates about their three primary drug platforms... The OSA drug they are awaiting manufacture of the new formulations per presentation. With roughly half of that funding looking to be in place and intent to list on the ASX, I can imagine they are only a few steps away from clinicals with the new formulations. I think we would all be interested in a status update on OSA. The recent PR on the spinal and ADHD candidate suggests trials later this year pending funding. That leaves the epilepsy/pain candidate drug in tier 3 of NIH. The CEO mentioned short term looking for opening up purse strings to support. Given the national attention to opioids, any promising drug that can mitigate the problem would be absolutely huge news and very valuable. I would speculate they are looking for a partner to help carry the ball across the goal line with respect to this drug candidate. As one can imagine, big pharma would highly seek this candidate for a multitude of reasons.
